ABSI

Absci Corp.'s stock price has experienced significant movements, gaining 173.1% over the last 12 months as of October 6, 2026. On May 7, 2026, Absci reported Q1 2026 financial results with $0.2 million revenue and a $29.6 million net loss, also announcing that ABS-201 completed four SAD cohorts and initiated MAD dosing. On June 24, 2026, the stock gained 35.96% after Absci reported positive early-stage data for its hair loss candidate ABS-201 and a subsequent $100 million stock offering backed by Eli Lilly, which funded its pipeline through key 2026-2027 milestones. On August 11, 2026, Q2 2026 results showed an EPS of -$0.21, missing estimates, and quarterly revenue of $0.32 million, below expectations; despite this, the stock closed higher due to momentum from positive ABS-201 data and the Eli Lilly-backed financing. On September 1, 2026, Absci announced participation in upcoming investor conferences. LifeSci Capital initiated coverage of Absci with an 'Outperform' recommendation on September 9, 2026. On September 24, 2026, Absci announced preliminary details for its Phase 2 STORYLINE™ trial of AI-Designed Antibody ABS-201™ for endometriosis, with anticipated initiation in mid-2027, which led to a 'sell-the-news' style pullback of around 10% on October 6, 2026. In October 2026, the stock experienced daily fluctuations, closing at $10.27 on October 6, 2026.